This is followed by autoantibody access to the brain, where anti-GluN1 autoantibodies cause a selective and reversible decrease in the synaptic localization of NMDARs, leading to the pathogenesis of cognitive deficits and neuropsychiatric symptoms observed in patients [39]. Here, GRIN1 is linked to Cognitive impairment.